Rheumatoid arthritis (after failure of previous antirheumatic drugs) - golimumab: final appraisal determination
After considering the feedback from consultation, the Appraisal Committee has prepared a Final Appraisal Determination (FAD) on Golimumab for the treatment of rheumatoid arthritis after the failure of previous disease-modifying antirheumatic drugs and submitted it to the Institute.
The FAD has been sent to the formal consultees for this appraisal who have 15 working days to consider whether they wish to appeal against it. Subject to any appeal by consultees, the FAD may be used as the basis for the Institute's guidance on the use of the appraised technology in the NHS in England and Wales.
Please note that the appeal period for this appraisal will close at 5pm on 27 May 2011.
Rheumatoid arthritis (after failure of previous antirheumatic drugs) - golimumab: final appraisal determination document
Patient Access Scheme
Report on the additional data and data requested following the second committee meeting produced by the School of Health and Related Research (ScHARR)
Additional data request
Response to request for re-modelling and additional information from Merck Sharp & Dohme (MSD)
Response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD)
Report on the additional data requested following the ACD produced by the School of Health and Related Research (ScHARR)
Consultee and commentator comments on the ACD
This page was last updated: 12 May 2011